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ABSTRACT
Background The use of flow diversion to treat 
intracranial aneurysms has increased in recent years.
Objective To assess the safety and angiographic 
efficacy of the p64 flow modulation device.
Methods Diversion- p64 is an international, prospective, 
multicenter, single- arm, study conducted at 26 centers. 
The p64 flow modulation device was used to treat 
anterior circulation aneurysms between December 2015 
and January 2019. The primary safety endpoint was 
the incidence of major stroke or neurologic death at 
3–6 months, with the primary efficacy endpoint being 
complete aneurysm occlusion (Raymond- Roy Occlusion 
Classification 1) on follow- up angiography.
Results A total of 420 patients met the eligibility 
criteria and underwent treatment with the p64 
flow modulation device (mean age 55±12.0 years, 
86.2% female). Mean aneurysm dome width was 
6.99±5.28 mm and neck width 4.47±2.28 mm. Mean 
number of devices implanted per patient was 1.06±0.47, 
with adjunctive coiling performed in 14.0% of the cases. 
At the second angiographic follow- up (mean 375±73 
days), available for 343 patients (81.7%), complete 
aneurysm occlusion was seen in 287 (83.7%) patients. 
Safety data were available for 413 patients (98.3%) 
at the first follow- up (mean 145±43 days) with a 
composite morbidity/mortality rate of 2.42% (n=10).
Conclusions Diversion- p64 is the largest prospective 
study using the p64 flow modulation device. The 
results of this study demonstrate that the device has 
a high efficacy and carries a low rate of mortality and 
permanent morbidity.
INTRODUCTION
The development and introduction of flow diverter 
stents into clinical practice was a pivotal moment in 
the treatment of cerebral aneurysms.1 2
It is now understood that devices constructed 
with an increased number of wires have a greater 
flow diverting effect3 and a lower variance in the 
flow diverting effect when there are changes in 
the caliber of the underlying vessel or in curved 
vessels.4
The p64 flow modulation device (p64 FMD, 
phenox GmbH, Germany) is constructed from 
64 braided nickel- titanium wires and designed to 
provide optimized flow diverting properties. The 
device is approved for the treatment of intracra-
nial aneurysms and dissections in Europe, and 
a growing body of literature supports its long- 
term efficacy.5–12 Diversion- p64 was a single- arm, 
international, multicenter, prospective study to 
assess the safety and efficacy of the p64 FMD and 
is the largest prospective study on flow diversion 
to date.
METHODS
Study design, enrollment, and patient selection
Diversion- p64 ( ClinicalTrials. gov identification 
code: NCT02600364) was a single- arm, inter-
national, multicenter, prospective study to assess 
the safety and efficacy of the p64 FMD. Between 
December 2015 and January 2019 patients were 
enrolled at 26 centers from 10 different countries, 
including eight European countries, Argentina and 
Russia (online supplemental figure 3). Recruiting 
sites had to be familiar with the p64 FMD. All 
participating sites were required to perform five 
‘lead- in cases’ with p64 FMD under the super-
vision of an experienced proctor prior to study 
participation.
The eligibility criteria are listed in the online 
supplemental material. The per- protocol popu-
lation contains all enrolled patients who met all 
eligibility criteria and had at least one p64 FMD 
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Study device
The p64 FMD received the Conformité Européenne (CE) mark 
in 2012. The p64 FMD is constructed from 64 braided nickel- 
titanium wires and is available in diameters ranging from 2.5 
to 5 mm and lengths ranging between 9–36 mm. Proximally, 
the 64 wires form eight bundles each of which has a proximal 
radiopaque marker. Two platinum wires allow radiopacity and 
visibility of the device in vivo. The p64 FMD is the only flow 
diverter available on the market that is mechanically detach-
able and this unique feature allows the device to be completely 
unsheathed, resheathed and to be delivered through a 0.027” 
inner diameter microcatheter.
Baseline assessments
Before placement of the p64 FMD, patients underwent a neuro-
logical assessment using the modified Rankin Scale (mRS) and 
National Institutes Health Stroke Scale (NIHSS). Medical history 
and concomitant medications were recorded. In case of ruptured 
aneurysms, the World Federation of Neurosurgeons classifica-
tion was also recorded.
Dual antiplatelet therapy
Consistent with the instructions for use for the p64 FMD, dual 
antiplatelet therapy was advised. The use of heparinization 
during the procedure was encouraged and the choice and dura-
tion of dual antiplatelet therapy was according to the local site- 
specific standard operating procedures. Preoperative testing of 
responsiveness to antiplatelets with point- of- care testing equip-
ment. such as VerifyNow (Accumetrics, San Diego, California, 
USA), was encouraged but not mandatory.
Follow-up assessments
Patients were assessed prior to discharge and when new neuro-
logical deficits were seen, cross- sectional imaging of the brain, 
with either CT or MRI, was performed. Two clinical and 
imaging follow- ups were scheduled between 3 and 6 months and 
7 and 12 months according to site- specific standard operating 
procedures.
Safety reporting
Investigators were required to report all adverse events 
and serious adverse events. An independent Clinical Events 
Committee (CEC) adjudicated all relevant adverse events and 
serious adverse events reported by the investigators or by the 
core laboratory and determined whether these were related to 
the device, the procedure, or both. The CEC consisted of three 
independent physicians with specialist expertise in neurological 
diseases and vascular neurology (composition listed in online 
supplemental material). The core laboratory reviewed the image 
material of all procedures, and any complication depicted on 
imaging that was not yet known from event reporting by 




The primary efficacy endpoint was the complete occlusion of 
the intracranial aneurysm, based on the Raymond- Roy Occlu-
sion Classification.13 An independent core laboratory, blinded 
to all clinical information, reconfirmed the aneurysm type and 
location, matched the eligibility criteria, and assessed the aneu-
rysm at both follow- up visits.
Before the core laboratory readers started their review, they 
were trained on the study protocol, schedule of imaging assess-
ments, and aligned on definitions and reading from a general 
perspective. All core laboratory members are licensed and prac-
ticing interventional neuroradiologists, each with over 10 years 
of experience in interventional neuroradiology and experience 
as core laboratory reader in previous studies. The members of 
the core laboratory were not practicing at any of the investi-
gational sites (composition listed in online supplemental mate-
rial). Two core laboratory readers performed a review of all 
patients independently from each other. The resulting data were 
compared, and in cases of discrepancy a third reader judged the 
case as an adjudicator.
Primary safety endpoint
The primary safety endpoint was the incidence of major stroke 
(ischemic or haemorrhagic) related to treatment of the target 
aneurysm, defined as an increase in the NIHSS score by 4 points 
or neurologic death at 3–6 months, with a secondary safety 
endpoint at 7–12 months after treatment.
Secondary endpoints
Secondary efficacy endpoints included technical feasibility to 
deliver and detach the p64 FMD at the correct location. Other 
secondary safety endpoints included evidence of aneurysm reca-
nalization or regrowth, intraprocedural complications such as 
vessel or aneurysm perforation, and thromboembolic compli-
cations as well as delayed postprocedural complications—for 
example, delayed aneurysmal rupture and infarction detected on 
follow- up imaging.
Statistical analysis
Demographics, baseline data, and procedural characteristics 
were summarized and reported as mean±SD and range for 
continuous variables. Categorical data were summarized using 
numbers and percentages.
The main hypothesis of the study was that the rate of neuro-
logical death and major stroke within 3–6 months after treat-
ment with the p64 FMD in patients with aneurysms in the 
anterior circulation was not inferior to the weighted mean rate 
of neurological death and major stroke within 6 months from 
three relevant studies at the time of study design and recruit-
ment. The weighted average rate of neurological death and 
major stroke within 3–6 months after treatment was calculated 
as 6.6% and derived from the results of three key publications 
using the Pipeline embolization devices (PED, Medtronic): 
Pipeline for the Intracranial Treatment of Aneurysms (PITA), 
Pipeline for Uncoilable or Failed Aneurysms (PUFS), Interna-
tional Retrospective Study of the Pipeline Embolization Device 
(IntrePED).14–16 A clinically acceptable non- inferiority margin 
of 4% was used. Based on this, a sample size of 348 patients 
completing the 3–6 months' follow- up was calculated to provide 
a power of 80% to meet the primary safety endpoint.
To evaluate non- inferiority a one- sided, one- sample binomial 
test was performed. The statistical analysis was performed in 
RStudio (version 4.0.3).
RESULTS
A total of 420 patients met all eligibility criteria and underwent 
treatment with the p64 FMD and constitute the per- protocol 
group on which this analysis has been performed.
The mean age of patients was 55±12.0 years (range 24–88) 
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was 6.99±5.28 mm (range 1.0–32.0 mm), with mean neck 
width 4.47±2.28 mm (range 1.0–15.0 mm). Very small aneu-
rysms (<4 mm) accounted for 31.4% of aneurysms. Of those 
131 small aneurysms, 22 (16.8%) were previously treated (21 
coiled and one clipped) and 17 (13%) were ruptured (one 
acutely and 16 previously). The majority of saccular aneu-
rysms (64%) were small (<7 mm) and 61.1% of aneurysm had 
a wide- neck (dome to neck ratio <1.5). Blister- like and fusi-
form aneurysms represented 3.8% and 1.2%, respectively, while 
dissecting aneurysms and segmental diseases were 1.0% each. 
The most common aneurysm locations were paraophthalmic 
(59.3%) and posterior communicating artery (16.9%). Most 
of aneurysms were asymptomatic (77.4%) and found inciden-
tally (66.4%). The vast majority of aneurysms were unruptured 
(93.3%) with seven aneurysms (1.67%) treated within 21 days 
of rupture. Most aneurysms had not been previously treated 
(86.9%). Of the previously treated aneurysms, the majority were 
coiled (n=52/55, 94.5%). Baseline aneurysm characteristics are 
summarized in table 1.
A total of 445 p64 FMDs were implanted and in the vast 
majority, a single p64 FMD was implanted (96.4%), with 
1.06±0.47 used for each patient. Adjunctive coiling was 
performed in 59/420 (14.0%) cases. In 98.1% of cases, the p64 
FMD was deployed at the desired location, with 97.4% with 
correct opening of the implanted p64 FMD (online supple-
mental table 1). In total, 442 implanted devices were detached 
correctly (99.3%).
Intraprocedural complications
In total, the core laboratory assessment determined that 23 
patients had an intraprocedural complication, with the most 
common being thromboembolism (n=17/420, 4.0%). These 
were managed using a variety of different strategies depending 
on local practice but included the use of antiplatelet agents, anti-
coagulants, and balloon angioplasty. Intraoperative vessel perfo-
ration occurred in two patients and intraoperative aneurysm 
perforation in one patient. Intraoperative side branch occlusion 
occurred in two patients and difficulty of device detachment was 
recorded in three cases.
Primary effectiveness endpoint
Angiographic follow- up data were available for 357 patients 
(85.0%) at the first follow- up performed at mean 145±43 
days (range 27–214 days). At this point, complete occlusion 
and residual neck were reported in 71.7% (n=256) and 4.5% 
(n=16) of cases, respectively, leading to 76.2% (n=272) cases of 
adequate occlusion.
At the second follow- up, performed at mean 375±73 days 
(range 245–579 days), angiographic data were available for 343 
patients (81.7%). The reasons for the missing angiographic 
assessments are reported in online supplemental figure 1. 
Complete aneurysm occlusion (figure 1) and residual neck were 
seen in 83.7% (n=287) and 2.3% (n=8) of cases, respectively, 
leading to 86.0% (n=295) of adequate occlusion.
Primary safety endpoint
Online supplemental figure 2 shows the disposition of safety 
data collected at three different time points during the study. 
Safety data were available for 413 patients (98.3%) at the 
first follow- up postprocedure. Of these 413 patients a major 
procedure- related stroke occurred in eight patients (1.9%). All 
were thromboembolic complications; seven occurred intrapro-
cedurally or periprocedurally, resulting in infarction with mass 
Table 1 Baseline aneurysm data
Characteristics Value Percentage
Aneurysm size n=417
  Dome width 6.99±5.28 mm (1.0–32.0 mm)
  Neck width 4.47±2.28 mm (1.0–15.0 mm)
  Very small (<4 mm) 131 31.4
  Small (≥4 – <7 mm) 136 32.6
  Medium (≥7 – <10 mm) 64 15.3
  Large (≥10 – <25 mm) 81 19.4
  Giant (≥25 mm) 5 1.2
Aneurysm Location n=420
  ICA, cavernous 49 11.7
  ICA, paraophthalmic 249 59.3
  PComA 71 16.9
  AChoA 18 4.3
  ICA, terminus 2 0.5
  ICA, petrous 2 0.5
  ACA, A1 segment 6 1.4
  MCA, M1 segment 14 3.3
  MCA, M2 segment 2 0.5
  ACA, distal. 1 0.2
  Anterior communicating artery 5 1.2
  ICA/MCA 1 0.2
Aneurysm morphology n=420
  Blister- like 16 3.8
  Dissecting 4 1.0
  Fusiform 5 1.2
  Saccular 391 93.1
  Segmental disease 4 1.0
Rupture status n=420
  Unruptured 392 93.3
  Previously ruptured 21 5
  Acutely ruptured (<21 days) 7 1.7
Previously treated n=420
  No 365 86.9
  Yes 55 13.1
Previous treatment n=55
  Previously coiled and flow 
diverted*
1 1.8
  Previously clipped 2 3.6
  Previously coiled 52 94.5
Clinical status of aneurysm n=420
Symptomatic
  No 325 77.4
  Yes 95 22.6
Incidental†
  No 141 33.6
  Yes 279 66.4
*Previously flow diverted with p64 flow modulatiion device.
†Aneurysms that were not ruptured, not symptomatic, and not previously treated.
ACA, anterior cerebral artery; AChoA, anterior choroidal artery; ICA, internal carotid 
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effect in three cases, with subsequent parenchymal hemorrhage 
in one case. One of the strokes occurred secondary to non- 
compliance with medication. Two patients were discharged with 
mild (NIHSS score 2) or no symptoms (NIHSS score 0) of stroke.
Mortality rate was 0.97% (n=4) related to a major stroke 
within the territory of the implanted device in two patients. In 
one case, a type A aortic dissection was discovered in the early 
postoperative period that resulted in myocardial infarction and 
death. In the last patient, death occurred 3 weeks postprocedure, 
secondary to a subdural hematoma that was thought to be caused 
by antiplatelet medication. The composite morbidity/mortality 
rate was therefore 2.42% (n=10/413) at the first follow- up. 
Comparing this rate with its 95% confidence interval (1.17% to 
4.43%) to the target of 6.6% adding the non- inferiority margin, 
results in a significant p value of <0.0001. The 95% exact upper 
CI was 4.43%, which was below the threshold of 10.6%; there-
fore, the primary safety endpoint of the study was met.
No further episodes of major stroke or death occurred 
between the first and second follow- up with data available for 
372 patients. Therefore, by the time of the second follow- up the 
composite endpoint was met in 2.69% of patients, with mortality 
seen in 1.08% and major neurological morbidity in 2.15%.
Secondary endpoints
No delayed aneurysmal ruptures or parenchymal hematomas 
were seen. A total of 23 patients with minor strokes at the first 
follow- up with one further minor stroke by the second follow- up 
were reported. Therefore, the minor stroke rate was 6.4% 
(n=24). Ischemic stroke was found in 22 cases (91.7%) within 
the first 4 days after implantation and in the remaining two 
cases there was no correlation between the clinical symptoms 
and the corresponding image material. Of those 22 patients, two 
received no antiplatelet medication before intervention and no 
additional bolus of antiplatelet medication during the proce-
dure, five patients were receiving single antiplatelet therapy, and 
the remaining 15 were receiving dual antiplatelet therapy. In 19 
of 24 patients, a P2Y12 receptor inhibition test was performed 
before implantation, and all were responders. All of those minor 
strokes and silent infarctions occurred in the same territory of 
the treated vessel, probably thromboembolic in origin. Of all 
the patients who had a minor stroke (n=24), five were clini-
cally silent (20.8%) and 12 had transient clinical symptoms 
that completely resolved (50%). In total, 23 of the 24 patients 
(95.8%) who had minor strokes were reported to have an mRS 
score of 0 and one patient an mRS score of 2.
In-stent stenosis
At the initial angiographic follow- up, in- stent stenosis of any 
degree was seen in 15.4% of cases (n=55/357) and the majority 
of these cases (n=31/55) were mild (<50%). Any degree of 
in- stent stenosis was seen in 8.7% of patients at the second 
follow- up (n=30/343). The majority of cases (5.5%, n=19/343) 
represented mild stenosis with only a single case of severe 
stenosis (≥75%).
Aneurysm growth, recanalization, and re-treatments
In total there were two aneurysm growths, one seen at the first 
follow- up (0.3%) and one seen at the second follow- up (0.3%). 
There were four aneurysm recanalizations (blood flow into the 
aneurysm increased compared with previous visit), two at the 
first follow- up (0.6%) and two at the second follow- up (0.6%).
Eight planned (1.9%) and two unplanned (0.5%) re- treat-
ments were carried out by the first follow- up and a further two 
planned re- treatments (0.5%) by the second follow- up.
DISCUSSION
Diversion- p64 is the largest prospective study looking at flow 
diversion using the p64 FMD to date. The results of the study 
were compared with similar devices available on the US and EU 
market.
Several previous publications have looked at the p64 FMD, 
but these reports have been retrospective with no core labora-
tory, no CEC, and no source data verification.6 7 10–12 Aguilar 
Pérez et al9 recently published a retrospective, single- center 
series of 530 patients harboring 617 unruptured saccular aneu-
rysms (or those treated >30 days post- rupture), located in the 
anterior circulation and treated with at least one p64 FMD. The 
majority of the aneurysms (562, 91.1%) were <10 mm, with an 
average aneurysm dome size of 4.8 mm (range 1–27 mm), and 
the p64 FMD procedure was the first treatment performed for 
515 (83.5%) of the aneurysms. Mid- term and delayed angio-
graphic follow- ups documented a progression of complete occlu-
sion from 76.6% to 86.4%, residual neck remnants in 8.1% and 
continued dome filling in 5.5% of aneurysms. The overall rate 
of thromboembolic complications was 4.8%. The permanent 
morbidity/mortality rate was 2.4%. Prior studies have shown 
similar results with progressive aneurysm occlusion over time 
and similar morbidity/mortality rates.6 Overall, the results of 
Diversion- p64 are similar to these previous studies, with a low 
permanent morbidity/mortality of 2.4% and adequate occlu-
sion rate of 86% seen on second angiographic follow- up. These 
results highlight the overall safety and efficacy of the p64 FMD.
The results of the Diversion- p64 study will be compared with 
similar prospective, multicenter studies using alternative flow 
diverter stents. A special focus on primary safety and efficacy 
endpoints is summarized in table 2. Even though those studies 
recruited mainly small and large wide- neck unruptured aneu-
rysms the data in table 2 should be taken with caution as inves-
tigators used different size grading scales, which makes relevant 
clinical performance comparisons between devices hazardous. 
For each of them, the narrative will be restricted to the main 
findings of the study.
Figure 1 A 6 mm right- sided, symptomatic paraophthalmic, saccular, 
aneurysm (A). The aneurysm was treated using a single 4×12 p64 
flow modulation device. A satisfactory position of the device (B) was 
confirmed on unsubtracted images (C). Significant contrast stagnation 
(D) could be seen at the end of the procedure. Control angiography 
performed at 4 months postprocedure showed complete occlusion of the 
aneurysm (E), that was confirmed on delayed angiography performed 
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The PREMIER study17 was a prospective, multicenter, 
single- arm trial to evaluate the safety and effectiveness of the 
Pipeline embolization device (PED, Medtronic) in the treat-
ment of aneurysms measuring ≤12 mm with a wide- neck, which 
enrolled 141 patients. The median aneurysm size was 4.6 mm 
(mean 5.0±1.92 mm), with the majority of the aneurysms 
treated being smaller than 7 mm (n=119, 84.4%).
The safety and efficacy analysis (SAFE) of the flow direction 
endoluminal device (FRED) in the aneurysm SAFE study18 was a 
prospective, single- arm, multicenter, observational French study 
that enrolled patients with 103 aneurysms, either unruptured 
(n=76, 73.8%) or recanalized (n=27, 26.2%). The majority 
of aneurysms (68.9%) were small (<10 mm) and wide- necked 
(96.1%). The most common locations were the cavernous and 
supraclinoid segments (83.5%) of the internal carotid artery.
Taschner et al19 recently published results from a prospective, 
international, multicenter trial assessing the Derivo emboliza-
tion device (DED, Acandis, Pforzheim, Germany). Inclusion 
criteria allowed enrollment of unruptured aneurysms of any 
size located within either the anterior or posterior circulation 
in patients with a mRS score of  ≤1. The study enrolled 119 
patients with median aneurysm and neck size of 14.2±16.9 mm 
and 7.7±9.6 mm, respectively, with predominantly saccular 
morphology (80%) and anterior circulation (88%).
Wakhloo et al20 published a prospective, international multi-
center, single- arm study assessing the Surpass (Stryker Neuro-
vascular, Kalamazoo, USA) device intended for the treatment 
of intracranial aneurysms of the anterior and posterior (14.5%) 
circulations. Successful flow- diverter delivery was achieved 
in 161 patients with 186 aneurysms (98%). The majority of 
aneurysms were <10 mm (n=117, 62.9%). Clinical follow- up 
was available for 150 patients (median 6 months; range 1–38 
months) and the primary safety endpoint (neurological death or 
major stroke) was met in 18 patients (11%). Permanent neuro-
logic morbidity and mortality were 6% and 2.7%, respectively. 
Morbidity occurred in 4% and 7.4% of patients treated for 
aneurysms of the anterior and posterior circulation, respectively. 
Of the 186 aneurysms treated, angiographic follow- up data were 
available for 158 aneurysms (86.8%) at a median of 6 months 
(range 1–38 months) with 75% complete occlusion (n=118).
In comparison with these previous studies, the results from 
Diversion- p64 are favorable. The mean aneurysm size in Diver-
sion- p64 was 6.99±5.28 mm, which is comparable to the afore-
mentioned studies. Although a substantial number of patients 
were lost between the first (6 months; 413/420, 93.3%) and last 
safety follow- up (12 months; 372/420, 88.6%), only a single 
minor stroke was recorded within this time frame. Even though 
primary safety endpoints could not be compared, owing to a lack 
of a common definition, the cumulative morbidity/mortality is 
comparable to similar studies (table 2).
Angiographic aneurysm occlusion rates were also very favor-
able, with 83.7% of aneurysms occluded at the second angio-
graphic follow- up, and 86% achieving adequate occlusion. In 
comparison with these previous studies, taking into account that 
Diversion- p64 has recruited the largest number of very small 
(<4 mm) aneurysms, the complete occlusion rate for the p64 
FMD exceeds that of the other devices on the market over a 
similar time span. The in- stent stenosis rate in Diversion- p64 is 
also comparable to rates reported for other devices. Ravindran 
et al21 recently described an in- stent stenosis rate of 7.4% in 
a cohort of 155 patients and 8.8% in their systematic review. 
In the earlier publication of John et al,22 38% of patients had 
some degree of luminal narrowing post PED implantation with 
9.8% having >25% in- stent stenosis. Similar rates of in- stent 
stenosis have been reported for the FRED (7.6%)23 and the DED 
(6.6%).24
Limitations
The main limitations of Diversion- p64 are the non- randomized 
nature and the lack of a control arm with inherent risk of selec-
tion bias. This has been acknowledged as several flow diverter 
stents were available in most of the participating centers and 
flow diverter selection was left to the treating physician. This 
bias can always be a component in a non- randomized study with 
flow diverters and was reduced by the number of 26 partici-
pating sites in 10 different countries. There is no long- term 
follow- up and heterogeneous use of antiplatelet medications 
and their duration. Angiographic imaging was not available 
for all patients and this might affect the overall occlusion rate. 
However, we believe that this is unlikely to be the case given 
previous studies on flow diversion and the improved occlusion 
rates seen on longer follow- up in the study. Furthermore, the 
majority of aneurysms included in the study were <10 mm, 
although most aneurysms were wide- necked. This was the case 
in several similar studies on flow diversion and the results of 
Diversion- p64 may not directly translate for occlusion rate and 
safety for large and giant aneurysms.
CONCLUSION
Diversion- p64 is the largest prospective study on the p64 FMD. 
The results of Diversion- p64 demonstrate one of the lowest rates 
of morbidity/mortality seen in any prospective study on flow 
Table 2 Safety and efficacy results of Diversion- p64 in comparison with similar prospective non- randomized studies involving other flow diverters
Study p64 (Diversion- p64) PED (PREMIER) FRED (SAFE) Surpass Derivo
Time point of last follow- up 12 months 12 months 12 months 6 months 18 months
Number of aneurysms 420 141 103 186 96
Anterior circulation 100% 95% 100% 85.5% 88%
Average aneurysm size (mm) 6.99±5.28 5.0±1.92 Not Reported 10.4±0.7 14.2±16.9
Percentage of adjunctive coiling 14% 3.5% 22.4% 19.3% 49%
Patients with safety follow- up at 12 months 88.6% 99.2% 95.1% 93.2% 93.8%
Morbidity 1.6% 1.4% 2.9% 6.0%* 3.1%
Mortality 1.1% 0.7% 1.9% 2.7%† 0.0%
Complete occlusion 83.7% 81.9% 73.3% 75% 82%
*4% permanent morbidity for treated anterior circulation aneurysms.
†1.7% mortality for treated anterior circulation aneurysms.
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diversion. It can be concluded that the device has a high efficacy 
and excellent safety profile that is comparable to other devices.
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